Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). - Wikidata - wikimedia - TriplyDB

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

http://www.wikidata.org/entity/Q33369071

about

Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patients Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).Management of metastatic germ cell tumors.Urologic oncology: Poor trial accrual hinders germ cell tumor therapy advances.Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours?

P2860

Q26797518-56DB286C-4397-4900-B11E-6D7DB7A4EEF2 Q33313043-A817561F-EB70-497D-B1F0-ED68B4A2EB0B Q35208183-E38CDDF7-6437-4BFA-9C6D-C78744A87DA8 Q35219992-CD56B8BF-93E0-43BF-96CA-F2534DC88DBC Q35540049-77ED3865-79F7-42D4-907D-C63F39C6770C Q37159527-27BBB67D-DA9B-4079-80A9-AE2D1926757F Q43674058-F9343762-9C11-4B91-8B5F-6E5D9A9FE050 Q55070614-DCF0EADC-C26E-4239-B2FD-50DBC87FF64B

P2860

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

http://www.wikidata.org/entity/Q33369071

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Intensive induction chemothera ...... l tumours (EORTC trial 30948).

@ast

Intensive induction chemothera ...... l tumours (EORTC trial 30948).

@en

type

label

Intensive induction chemothera ...... l tumours (EORTC trial 30948).

@ast

Intensive induction chemothera ...... l tumours (EORTC trial 30948).

@en

prefLabel

Intensive induction chemothera ...... l tumours (EORTC trial 30948).

@ast

Intensive induction chemothera ...... l tumours (EORTC trial 30948).

@en

P1433

Q33369071-E30D5460-B5E3-45DD-A1DA-B38D740CD468

P1476

Q33369071-FA2997F1-91AA-4847-AF88-1BB8CCC32611

P2093

Q33369071-012AD784-55A1-4B34-8AA3-9B56E5E33A39

Q33369071-1139E8D1-82AF-40E4-99E6-D48588815933

Q33369071-17706635-2A9E-48B6-AD68-3749D0616014

Q33369071-1C6A676F-E35F-4223-BAA8-CDDE09411223

Q33369071-2172FCF5-E81A-4D9E-99D7-A8857D9B7446

Q33369071-39557A6C-FFE4-4A24-851C-88E0EF8144C4

Q33369071-49070D6B-37F5-493A-A371-6B5EA18E0BA5

Q33369071-7FE27EA2-3558-4E46-83AC-B2B4EB7F5EF0

Q33369071-A58DA5D1-31B1-400F-B552-2327846F80F5

Q33369071-C03D2C90-4974-4289-8A85-66603CCFBAFC

P2860

Q33369071-0AA3C4CC-C360-4FA9-927D-37655A4B3B52

Q33369071-25B988B5-133F-485A-89BF-D6983B54C11E

Q33369071-270F07EB-2900-483F-BE98-6872E6357406

Q33369071-2B1CB503-8C82-4ACE-A18F-54120F32B702

Q33369071-2DDA8F11-B462-43F1-97C8-A17BFF8D352B

Q33369071-4BF470CD-0FF7-494B-B75B-95FCE795792A

Q33369071-51EF8513-D958-4262-8DD9-E76ADAE1F90C

Q33369071-655937F6-5699-4D10-B4F7-FD90D4EECA50

Q33369071-726317DF-9CA3-405B-BA9C-CDE6DB75D441

Q33369071-7A6728EB-1E14-4AFD-B62D-1B2759814A33

P2888

Q33369071-3BD46FC0-6F7D-4EEF-88A8-82CDE339AD99

P304

Q33369071-9CFB2E7C-AE63-45A3-AD38-25AFB584AA20

P31

Q33369071-5E2CB49D-F709-472C-A230-99C2B5ED23D3

P356

Q33369071-9EB07006-B12A-4979-8564-D6E91BCD84C6

P407

Q33369071-DF295F09-AB8B-4A5B-ACE4-7E7098E3E5C2

P433

Q33369071-5495D4BF-21B9-4636-8D62-BC8594B5AF17

P478

Q33369071-937825DA-A25C-46B7-BA8F-697DFB2245DD

P50

Q33369071-369483B6-EE33-4AA5-84A5-FAC029E27165

P577

Q33369071-3E54F6D3-512B-4394-BF26-C13040E352BC

P5875

Q33369071-E76A956A-E67B-4A54-8894-109214DF3C26

P6179

Q33369071-7658E4CE-CF1E-4D6E-AD23-D58AC708789C

P698

Q33369071-F1254344-F40F-4D8D-BF63-129DAF8E6CB4

P932

Q33369071-AF1DF1B5-60C7-4C38-B83C-C8DAA132486E

P356

P1433

British Journal of Cancer

P1476

Intensive induction chemothera ...... l tumours (EORTC trial 30948).

@en

P2093

A Horwich

http://www.w3.org/2001/XMLSchema#string

A T van Oosterom

http://www.w3.org/2001/XMLSchema#string

B Paluchowska

http://www.w3.org/2001/XMLSchema#string

EORTC GU Group

http://www.w3.org/2001/XMLSchema#string

G Kaiser

http://www.w3.org/2001/XMLSchema#string

L Collette

http://www.w3.org/2001/XMLSchema#string

L de Prijck

http://www.w3.org/2001/XMLSchema#string

O Koriakine

http://www.w3.org/2001/XMLSchema#string

P H M de Mulder

http://www.w3.org/2001/XMLSchema#string

R de Wit

http://www.w3.org/2001/XMLSchema#string

P2860

A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.

Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors.

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Ca

First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.

Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.

Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.

Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Ca

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of C

P2888

P304

1209-1214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602830

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Sophie D. Fosså

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7514672

http://www.w3.org/2001/XMLSchema#string

P6179

1033256343

http://www.w3.org/2001/XMLSchema#string

P698

16251877

http://www.w3.org/2001/XMLSchema#string

P932

2361516

http://www.w3.org/2001/XMLSchema#string